Skip to main content
SpringerLink
Log in

Chemotherapy for Childhood Orbital Tumors

  • Chapter
  • First Online:
Book cover Orbital Tumors

  • 1515 Accesses

Abstract

Orbital tumors in the pediatric population are a rare event. The differential diagnosis for these tumors is broad, but only a small number of these lesions are malignant. In this chapter the chemotherapy used for the treatment of the following conditions will be discussed: (1) primary malignant orbital tumors such as rhabdomyosarcoma, lymphoma, and myeloid sarcoma; (2) malignancies that may metastasize to the orbit including neuroblastoma, Ewing sarcoma, and Wilms tumor; (3) malignancies that can invade the orbit such as retinoblastoma, optic nerve glioma, and esthesioneuroblastoma; and (4) nonmalignant processes including hemangiomas and Langerhans cell histiocytosis. A multidisciplinary team approach is essential to the treatment of these tumors in order to provide children with the best and most appropriate care possible. The treatments for these tumors are constantly evolving, and given the rarity of most of these conditions, understanding and improvement in outcomes will come about only with a cooperative, multidisciplinary approach within the context of large group trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.

  2. Rootman J, editor. Frequency and differential diagnosis. In: Diseases of the orbit: a multidisciplinary approach. Philadelphia: JB Lippincott; 1988. p. 124.

    Google Scholar 

  3. Shields JA, Blakwell B, Augsburger JJ, et al. Spacy-occupying orbital masses in children. A review of 250 consecutive biopsies. Opthalmology. 1986;93:379–84.

    CAS  Google Scholar 

  4. Ognjanovic S, Linabery AM, Charbonneau B, et al. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2006. Cancer. 2009;115(18):4218–26.

    PubMed  PubMed Central  Google Scholar 

  5. Mauer HM, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993;71:1904–22.

    Google Scholar 

  6. Wexler LH, Crist WM, Helman LJ. Rhabdomyosarcoma and the undifferentiated sarcomas. In: Pero PA, Poplack DG, editors. Principles and practice of pediatric oncology. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2002. p. 939–71.

    Google Scholar 

  7. Jones IS, Reese AB, Krout J. Orbital rhabdomyosarcoma: an analysis of sixty-two cases. Trans Am Ophthalmol Soc. 1965;63:223–5.

    PubMed  CAS  PubMed Central  Google Scholar 

  8. Frayer WC, Enterline HT. Embryonal rhabdomyosarcoma of the orbit in children and young adults. AMA Arch Opthalmol. 1959;62:203.

    CAS  Google Scholar 

  9. Sagerman RH, Cassady JR, Tretter P. Radiation therapy for rhabdomyosarcoma of the orbit. Trans Am Acad Ophthalmol Otol. 1968;72:849–54.

    CAS  Google Scholar 

  10. Aviles E. Rhabdomyosarcoma of the orbit. Int Surg. 1974;59:297–9.

    PubMed  CAS  Google Scholar 

  11. Abramson DH, Ellsworth RM, et al. The treatment of orbital rhabdomyosarcoma with irradiation and chemotherapy. Ophthalmology. 1979;86:330–5.

    Google Scholar 

  12. Jereb B, Haik BG, et al. Parameningeal rhabdomyosarcoma (including the orbit): results of orbital irradiation. Int J Radiat Oncol Biol Phys. 1985;11:2057–65.

    PubMed  CAS  Google Scholar 

  13. Raney RB, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma. 2001;5:9–15.

    PubMed  CAS  PubMed Central  Google Scholar 

  14. Sutow WW, Lindberg RD, Gehan EA, et al. Three-year relapse-free survival rates in childhood rhabdomyosarcoma of the head and neck. Report from the Intergroup Rhabdomyosarcoma Study. Cancer. 1982;49:2217.

    PubMed  CAS  Google Scholar 

  15. Heyn R, Ragab A, Raney B, et al. Late effects of therapy in orbital rhabdomyosarcoma in children. A report from the Intergroup Rhabdomyosarcoma Study. Cancer. 1986;57:1738.

    PubMed  CAS  Google Scholar 

  16. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988;61:209.

    PubMed  CAS  Google Scholar 

  17. Wharan MD, Hanfelt JJ, Tefft MC, et al. Radiation therapy for rhabdomyosarcoma: local failure risk for clinical group III patients on Intergroup Rhabdomyosarcoma Study II. Int J Radiat Oncol Biol Phys. 1997;4:797.

    Google Scholar 

  18. Crist WM, et al. Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II. J Clin Oncol. 1990;8:443–52.

    PubMed  CAS  Google Scholar 

  19. Heyn R, Haeberlen V, Newton WA, et al. Second malignant neoplasms in children treated for rhabdomyosarcoma. J Clin Oncol. 1993;11:262.

    PubMed  CAS  Google Scholar 

  20. Crist WM, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610.

    PubMed  CAS  Google Scholar 

  21. Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study IV: results on patients with nonmetastatic disease. J Clin Oncol. 2001;19:3091.

    PubMed  CAS  Google Scholar 

  22. Reiter A. Diagnosis and treatment of childhood non-Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2007;285–96.

    Google Scholar 

  23. Meadows AT, Sposto R, et al. Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin’s lymphoma of children: a report from the Children’s Cancer Study Group. J Clin Oncol. 1989;7:92–9.

    PubMed  CAS  Google Scholar 

  24. Patte C, Philip T, et al. High survival rate in advanced stage B cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy. Results of a randomized trial from the French Pediatric Oncology Society (SFOP) on 216 children. J Clin Oncol. 1991;9:123.

    PubMed  CAS  Google Scholar 

  25. Suryanarayan K, Schuster JJ, et al. Treatment of localized primary non-Hodgkin’s lymphoma of bone in children: a Pediatric Oncology Group study. J Clin Oncol. 1999;17:456–9.

    PubMed  CAS  Google Scholar 

  26. Link MP, Schuster JJ, et al. Treatment of children and young adults with early stage non-Hodgkin’s lymphoma. N Engl J Med. 1997;337:1259–66.

    PubMed  CAS  Google Scholar 

  27. Gerrard M, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141:840–7.

    PubMed  CAS  Google Scholar 

  28. Link MP, Donaldson SS, et al. Results of treatment of childhood localized non-Hodgkin’s lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med. 1990;322:1169–74.

    PubMed  CAS  Google Scholar 

  29. Anderson J, Wilson J, et al. Childhood non-Hodgkin’s lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2L2). N Engl J Med. 1983;308:559.

    PubMed  CAS  Google Scholar 

  30. Anderson J, Jenkin D, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin’s lymphoma: a report of CCG-551 from the Children’s Cancer Group. J Clin Oncol. 1993;11:1024.

    PubMed  CAS  Google Scholar 

  31. Reiter A. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Franfurt-Munster Group trial NHL-BFM 90. Blood. 1999;94:3294–306.

    PubMed  CAS  Google Scholar 

  32. Woessmann W, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948–58.

    PubMed  CAS  Google Scholar 

  33. Patte C, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80.

    PubMed  CAS  PubMed Central  Google Scholar 

  34. Cairo MS, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736–43.

    PubMed  CAS  PubMed Central  Google Scholar 

  35. Patte C, Philip T, et al. Improved survival rate in children with stage III and IV B cell NHL and leukemia using a multiagent chemotherapy: results of a study of 114 children from SFOP. J Clin Oncol. 1986;4:1219.

    PubMed  CAS  Google Scholar 

  36. Sullivan MP, Ramirez I. Curability of Burkitt’s lymphoma with high dose cyclophosphamide, high dose methotrexate therapy and intrathecal chemoprophylaxis. J Clin Oncol. 1985;3:627.

    PubMed  CAS  Google Scholar 

  37. Patte C, Kalifa C, et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992;20:105.

    PubMed  CAS  Google Scholar 

  38. Reiter A, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM Group report. Blood. 2000;95:416–21.

    PubMed  CAS  Google Scholar 

  39. Burkhardt B, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006;24:491–9.

    PubMed  Google Scholar 

  40. Menasce LP, Banerjee SS, et al. Extramedullary myeloid tumor (granulocytic sarcoma) is often misdiagnosed: a study of 26 cases. Histopathology. 1999;34:391–8.

    PubMed  CAS  Google Scholar 

  41. Byrd JC, Edenfield J, et al. Extramedullary myeloid cell tumors in acute nonlymphoblastic leukemia: a clinical review. J Clin Oncol. 1995;13:1800.

    PubMed  CAS  Google Scholar 

  42. Cavdar AO, Babacan E, et al. High risk subgroup of acute myelomonocytic leukemia with orbito-ocular granulocytic sarcoma in Turkish children. Acta Haematol. 1989;81:80.

    PubMed  CAS  Google Scholar 

  43. Shome DK, Gupta NK, et al. Orbital granulocytic sarcomas (myeloid sarcoma) in acute nonlymphoblastic leukemia. Cancer. 1992;70:2298–301.

    PubMed  CAS  Google Scholar 

  44. Johnston DL, et al. Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;58:519–24.

    PubMed  PubMed Central  Google Scholar 

  45. Felice MS, Zubizarreta PA, et al. Good outcome of children with acute myeloid leukemia and t(8;21)(q22;q22), even when associated with granulocytic sarcoma. A report from a single institution in Argentina. Cancer. 2000;88:1939–44.

    PubMed  CAS  Google Scholar 

  46. Buckley JD, et al. Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group. Cancer. 1989;63:1457–65.

    PubMed  CAS  Google Scholar 

  47. Smith FO, et al. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children’s Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia. 2005;19:2054–62.

    PubMed  CAS  Google Scholar 

  48. Wells R, et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia. A report from the Childrens Cancer Group Study. J Clin Oncol. 1994;12:2367–77.

    PubMed  CAS  Google Scholar 

  49. Lange BJ, et al. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children’s Cancer Group Study 2941. J Clin Oncol. 2004;22:150–6.

    PubMed  CAS  Google Scholar 

  50. Horan JT, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children’s Oncology Group. J Clin Oncol. 2008;26:5797–801.

    PubMed  PubMed Central  Google Scholar 

  51. Niewerth D, et al. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116:2205–14.

    PubMed  CAS  Google Scholar 

  52. Gibson BE, et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol. 2011;155:366–76.

    PubMed  CAS  Google Scholar 

  53. National Cancer Institute. Bortezomib and sorafenib tosylate in treating patients with newly diagnosed acute myeloid leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011 [cited 2013 Feb 27]. http://clinicaltrials.gov/show/NCT01371981. NLM Identifier: NCT01371981.

  54. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am. 2008;55:97–120.

    PubMed  Google Scholar 

  55. Marris J. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–11.

    Google Scholar 

  56. Matthay KK, Villablanca JG, et al. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplant and 13-cis-retinoic acid. A Children’s Cancer Group Study. N Engl J Med. 1999;341:1165.

    PubMed  CAS  Google Scholar 

  57. Granger M, et al. Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;59:902–7.

    PubMed  Google Scholar 

  58. Children’s Oncology Group; National Cancer Institute. Comparing two different myeloablation therapies in treating young patients who are undergoing a stem cell transplant for high-risk neuroblastoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 20107 [cited 2013 Feb 27]. http://clinicaltrials.gov/show/NCT00567567. NLM Identifier: NCT00567567.

  59. Pearson ADJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9:247–56.

    PubMed  CAS  Google Scholar 

  60. Yu A, et al. Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34.

    PubMed  CAS  PubMed Central  Google Scholar 

  61. Kushner BK, et al. Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001;19:4189–94.

    PubMed  CAS  Google Scholar 

  62. Jedlika P. Ewing sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol. 2010;3:338–47.

    Google Scholar 

  63. Oberlin O, et al. Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001;85:1646–54.

    PubMed  CAS  PubMed Central  Google Scholar 

  64. Wunder J, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am. 1998;80:1020–33.

    PubMed  CAS  Google Scholar 

  65. Apple DJ. Wilms’ tumor metastatic to the orbit. Arch Opthalmol. 1968;80:480.

    CAS  Google Scholar 

  66. Fratkin JD, Purcell JJ, et al. Wilms’ tumor metastatic to the orbit. JAMA. 1977;238:1841.

    PubMed  CAS  Google Scholar 

  67. Rowe S, Siegel S, Benedict W. Ophthalmologic manifestations of genitourinary diseases. Urology. 1992;39:523.

    PubMed  CAS  Google Scholar 

  68. Canturk S, et al. Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol. 2010;94:1432–6.

    PubMed  CAS  Google Scholar 

  69. Ellsworth RM. Treatment of retinoblastoma. Am J Ophthalmol. 1968;66:49.

    PubMed  CAS  Google Scholar 

  70. Hyman GA, Ellsworth RM, et al. Combination therapy in retinoblastoma. A 15-year summary of methods and results. Arch Ophthalmol. 1968;80:744.

    PubMed  CAS  Google Scholar 

  71. Pratt CB, Crom DB, Howarth C. The use of chemotherapy for extraocular retinoblastoma. Med Pediatr Oncol. 1985;13:330–3.

    PubMed  CAS  Google Scholar 

  72. Goble RR, McKenzie J, et al. Orbital recurrence of retinoblastoma successfully treated by combined therapy. Br J Ophthalmol. 1990;74:97–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  73. Advani SH, Rao SR, et al. Pilot study of sequential combination chemotherapy in advanced and recurrent retinoblastoma. Med Pediatr Oncol. 1994;22:125–8.

    PubMed  CAS  Google Scholar 

  74. Doz F, Khelfaoui F, et al. The role of chemotherapy in orbital involvement of retinoblastoma. The experience of a single institution with 33 patients. Cancer. 1994;74:722–32.

    PubMed  CAS  Google Scholar 

  75. Schvartzman E, Chantada G, et al. Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol. 1996;14:1532–6.

    PubMed  CAS  Google Scholar 

  76. Doz F, Neuenschwandwer S, et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Societé Française d’Oncolgie Pédiatrique. J Clin Oncol. 1995;13:902–9.

    PubMed  CAS  Google Scholar 

  77. Chantada GL, Fandino A, et al. Phase II window of idarubicin in children with extraocular retinoblastoma. J Clin Oncol. 1999;17:1847–50.

    PubMed  CAS  Google Scholar 

  78. Chantada G, Fandino A, et al. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol. 2003;40:158–61.

    PubMed  Google Scholar 

  79. Antoneli C, et al. The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol. 2007;29:700–4.

    PubMed  CAS  Google Scholar 

  80. Radhakrishan V, et al. Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy. Ophthalmology. 2012;119:1470–7.

    Google Scholar 

  81. Harbour JW. Overview of RB gene mutations in patients with retinoblastoma. Implications for clinical genetic screening. Ophthalmology. 1998;105:1442–7.

    PubMed  CAS  Google Scholar 

  82. Ward P, Packman S, Loughman W, et al. Location of the retinoblastoma susceptibility gene(s) and the human esterase D locus. J Med Genet. 1984;21:92–5.

    PubMed  CAS  PubMed Central  Google Scholar 

  83. Francke U. Retinoblastoma and chromosome 13. Cytogenet Cell Genet. 1976;16:131–4.

    PubMed  CAS  Google Scholar 

  84. Squire J, Gallie BL, Phillips RA. A detailed analysis of chromosomal changes in heritable and nonheritable retinoblastoma. Hum Genet. 1985;70:291–301.

    PubMed  CAS  Google Scholar 

  85. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85:1121–8.

    PubMed  CAS  Google Scholar 

  86. Hansen MF, Koufos A, Gallie BL, et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A. 1985;82:6216–20.

    PubMed  CAS  PubMed Central  Google Scholar 

  87. Harbour JW, Lai S-L, Whang-Peng J, et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988;241:353–7.

    PubMed  CAS  Google Scholar 

  88. T’ang A, Varley JM, Chakraborty S, et al. Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science. 1988;242:263–6.

    PubMed  Google Scholar 

  89. DerKinderen DJ, Koten JW, Nagelkerke NJ, et al. Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int J Cancer. 1988;41:499–504.

    PubMed  CAS  Google Scholar 

  90. Draper GJ, Sanders BM, Kingston JE, et al. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53:661–71.

    PubMed  CAS  PubMed Central  Google Scholar 

  91. Leuder GT, Judisch F, O’Gorman TW. Second nonocular tumors in survivors of heritable retinoblastoma. Arch Ophthalmol. 1986;104:372–3.

    Google Scholar 

  92. Desjardins L, Haye C, Schlienger P, et al. Second nonocular tumors in survivors of bilateral retinoblastoma. A 30-year follow-up. Ophthalmic Pediatr Genet. 1991;12:145–8.

    CAS  Google Scholar 

  93. Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology. 1988;95:1583–7.

    PubMed  CAS  Google Scholar 

  94. Karcioglu ZA, Al-Rasheed W, Gray AJ. Second malignant neoplasms in retinoblastoma. Med East J Ophthalmol. 1997;5:99–104.

    Google Scholar 

  95. Abramson DH, Ellsworth RM, Kitchin FD, et al. Second nonocular tumors in retinoblastoma survivors. Are they radiation induced? Ophthalmology. 1984;91:1351–5.

    PubMed  CAS  Google Scholar 

  96. DeSutter E, Mesmer E, Hoepping H. Retinoblastoma: importance of time interval in onset of second tumors. Bull Soc Belge Ophthalmol. 1986;213:27–40.

    CAS  Google Scholar 

  97. Shields CA, Shields JA, Meadows AT. Chemoreduction for retinoblastoma may prevent trilateral retinoblastoma [letter]. J Clin Oncol. 2000;18:236–7.

    PubMed  CAS  Google Scholar 

  98. Petronio J, Edwards MS, et al. Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg. 1997;74:701.

    Google Scholar 

  99. Packer RJ, Ater J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86:747.

    PubMed  CAS  Google Scholar 

  100. Mahoney DH, Cohen ME, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neurooncology. 2000;2:213.

    Google Scholar 

  101. Fisher MJ, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012;14:790–7.

    PubMed  PubMed Central  Google Scholar 

  102. Avery RA, et al. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol. 2014;132:111–4.

    PubMed  Google Scholar 

  103. Morita A, Ebersold MJ, Olsen KD, et al. Ethesioneuroblastoma: prognosis and management. Neurosurgery. 1993;32:706–15.

    PubMed  CAS  Google Scholar 

  104. Porter AB, et al. Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol. 2008;90:201–4.

    PubMed  Google Scholar 

  105. Oskouian R, et al. Esthesioneuroblastoma: clinical presentation, radiological and pathological features, treatment, review of the literature and the University of Virginia experience. Neurosurg Focus. 2002;12:e4.

    PubMed  Google Scholar 

  106. Foote RL, et al. Esthesioneuroblastoma: the role of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 1993;27:835–42.

    PubMed  CAS  Google Scholar 

  107. Hamad K, Fayos J. Role of radiation therapy in the treatment of olfactory neuroblastoma. Int J Radiat Oncol Biol Phys. 1980;6:349–52.

    Google Scholar 

  108. Sheehan JM, Sheehan JP, Jane JA, et al. Chemotherapy for esthesioneuroblastomas. Neurosurg Clin North Am. 2000;11:693–701.

    CAS  Google Scholar 

  109. Bhattacharyya N, Thornton AF, Joseph MP, et al. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation: results in 9 cases. Arch Otolaryngol Head Neck Surg. 1997;123:34–40.

    PubMed  CAS  Google Scholar 

  110. Resto VA, Eisele DW, Forastiere A, et al. Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck. 2000;22:550–8.

    PubMed  CAS  Google Scholar 

  111. McElroy EA, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery. 1998;42:1023–7.

    PubMed  Google Scholar 

  112. Chamberlain C. Treatment of intracranial metastatic esthesioneuroblastoma. J Clin Oncol. 2002;20:357–8.

    PubMed  Google Scholar 

  113. Polin RS, Sheehan JP, Chenelle AG, et al. The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma: the University of Virginia experience. Neurosurgery. 1998;42:1029–37.

    PubMed  CAS  Google Scholar 

  114. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001;2:683–90.

    PubMed  CAS  Google Scholar 

  115. Soumekh B, Adams GA, Shapiro RS. Treatment of head and neck hemangiomas with recombinant interferon alpha 2. Ann Otol Rhinol Laryngol. 1996;105:201–6.

    PubMed  CAS  Google Scholar 

  116. Hemangioma Investigator Group, Haggstrom A, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr. 2007;150:291–4.

    Google Scholar 

  117. Burton B, et al. An increased incidence of haemagiomas in infants born following chorionic villus sampling (CVS). Prenat Diagn. 1995;15:209–14.

    PubMed  CAS  Google Scholar 

  118. Chang LC, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122:360–7.

    PubMed  Google Scholar 

  119. Haik BG, Karcioglu ZA, Gordon RA, Pechous BP. Capillary hemangioma (infantile periocular hemangioma). Surv Ophthalmol. 1994;38:399–426.

    PubMed  CAS  Google Scholar 

  120. Sadan N, Wolach B. Treatment of hemangiomas of infants with high doses of prednisone. J Pediatr. 1996;128:141–6.

    PubMed  CAS  Google Scholar 

  121. Ozsoylyu S. Megadose methylprednisolone therapy for Kasabach-Merritt syndrome [letter]. J Pediatr. 1996;129:947.

    Google Scholar 

  122. Stanley P, Geer GD, et al. Infantile hepatic hemangiomas. Clinical features, radiologic investigations, and treatment of 20 patients. Cancer. 1989;64:936–49.

    PubMed  CAS  Google Scholar 

  123. Ceisler E, Blei F. Ophthalmic Issues in hemangiomas of infancy. Lymphat Res Biol. 2003;1:321–30.

    PubMed  Google Scholar 

  124. Kushner BJ. Intralesional corticosteroid injection for intantile adnexal hemangioma. Am J Ophthalmol. 1982;93:496–506.

    PubMed  CAS  Google Scholar 

  125. Kushner BJ. The treatment of periorbital infantile hemangioma with intralesional corticosteroid. Plast Reconstr Surg. 1985;76:517–26.

    PubMed  CAS  Google Scholar 

  126. Iwananka T, Tsuchida Y, et al. Intralesional corticosteroid injection with short-term oral prednisolone for infantile hemangiomas of the eyelid and orbit. J Pediatr Surg. 1994;29:482–6.

    Google Scholar 

  127. Elsas FJ, Lewis AR. Topical treatment of periocular capillary hemangioma. J Pediatr Ophthalmol Strabismus. 1994;31:153–6.

    PubMed  CAS  Google Scholar 

  128. Cruz OA, Zarnegar SR, et al. Treatment of periocular capillary hemangioma with topical clobetasol propionate. Ophthalmology. 1995;102:2012–5.

    PubMed  CAS  Google Scholar 

  129. Taban M, Goldberg R. Propranolol for orbital heamangioma. Ophthalmology. 2010;117:195e4.

    Google Scholar 

  130. Al Dhaybi R, et al. Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children. Ophthalmology. 2011;118:1184–8.

    PubMed  Google Scholar 

  131. Léauté-Labrèz C, et al. Propranolol for severe hemangiomas of infancy [letter]. N Engl J Med. 2008;358:2649–51.

    Google Scholar 

  132. Kim LH, et al. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg. 2011;46:759–63.

    PubMed  Google Scholar 

  133. Drolet BA, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131:128–40.

    PubMed  PubMed Central  Google Scholar 

  134. Siegel DH, et al. Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) syndrome: a systematic review of the literature. Stroke. 2012;43:1672–4.

    PubMed  Google Scholar 

  135. Metry D, et al. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants. Pediatr Dermatol. 2013;30:71–89.

    PubMed  Google Scholar 

  136. Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol. 2010;146:564–5.

    PubMed  Google Scholar 

  137. Chakkittakandiyil A, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol. 2012;29:28–31.

    PubMed  Google Scholar 

  138. Chan H, et al. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics. 2013;131: e1739–47.

    PubMed  Google Scholar 

  139. Ezekowitz RAB, Mullikin JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456–63.

    PubMed  CAS  Google Scholar 

  140. Hastings MM, Barsoum-Homsey MJ, et al. Recombinant interferon alfa-2b in the treatment of vision-threatening capillary hemangiomas in childhood. J Am Assoc Pediatr Ophthalmol Strabismus. 1997;1:226–30.

    CAS  Google Scholar 

  141. Payarols JP, Masferrer JP, Gomez C. Treatment of life-threatening infantile hemangiomas with vincristine [correspondence]. New Engl J Med. 1995;333:69.

    Google Scholar 

  142. Hurvitz CH, Alkalay AL, et al. Cyclophosphamide therapy in life-threatening vascular tumors. J Pediatr. 1986;109:360–3.

    PubMed  CAS  Google Scholar 

  143. Kilpatrick SE, Enger DE, Gilchrist GS, et al. Langerhans cell histiocytosis (histiocytosis X) of the bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer. 1995;76:2471–84.

    PubMed  CAS  Google Scholar 

  144. Lee Y, Fay A. Orbital Langerhans cell histiocytosis. Int Ophthalmol Clin. 2009;49:123–31.

    PubMed  Google Scholar 

  145. Stromber JS, Wang AM, Huang TE, et al. Langerhans cell histiocytosis involving the sphenoid sinus and superior orbital fissure. AJNR Am J Neuroradiol. 1995;16:964–7.

    Google Scholar 

  146. LaBorwit SE, Karesh JW, Hirschbein MJ, et al. Multifocal Langerhans cell histiocytosis involving the orbit. J Pediatr Ophthalmol Strabismus. 1998;35:234–6.

    PubMed  CAS  Google Scholar 

  147. Erly WK, Carmody RF, Dryden RM. Orbital histiocytosis X. AJR Am J Neuroradiol. 1995;16:1258–61.

    CAS  Google Scholar 

  148. Egeler RM, Thompson RC. Intralesional infiltration of corticosteroids in localized Langerhans cell histiocytosis. J Pediatr Orthop. 1992;12:811.

    PubMed  CAS  Google Scholar 

  149. Ladisch S, Gadner H, et al. LCA-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol. 1994;23:107.

    PubMed  CAS  Google Scholar 

  150. Ceci A, DeTerlizzi M, et al. Etoposide in recurrent childhood Langerhans cell histiocytosis: an Italian cooperative study. Cancer. 1988;62:2528.

    PubMed  CAS  Google Scholar 

  151. Gramatovici R, D’Angio GJ. Radiation therapy in soft tissue lesions in histiocytosis X (Langerhans cell histiocytosis). Med Pediatr Oncol. 1988;16:259.

    PubMed  CAS  Google Scholar 

  152. Selch MT, Parker RG. Radiation therapy in the management of Langerhans cell histiocytosis. Med Pediatr Oncol. 1990;18:97.

    PubMed  CAS  Google Scholar 

  153. Donadieu J, Thomas C, Brugueres L, et al. for the French Langerhans Cell Study Group. A multicenter retrospective survey of Langerhans cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child. 1996;75:17–24.

    Google Scholar 

  154. Egeler RM, de Kraker J, Voute PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Ped Oncol. 1993;21:265–70.

    CAS  Google Scholar 

  155. Ceci A, de Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X’83 study. Med Pediatr Oncol. 1993;21:259–64.

    PubMed  CAS  Google Scholar 

  156. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans cell histiocytosis. J Pedatr. 2001;138: 728–34.

    CAS  Google Scholar 

  157. Gadner H, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111:2556–62.

    PubMed  CAS  Google Scholar 

  158. Gadner H, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121:5006–14.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jack Martin Division of Pediatric Hematology/Oncology, The Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY, 10029-6574, USA

    Jaclyn C. Davis M.D.

Authors
  1. Jaclyn C. Davis M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaclyn C. Davis M.D. .

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, USA

    Zeynel A. Karcioglu

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Davis, J.C. (2015). Chemotherapy for Childhood Orbital Tumors. In: Karcioglu, Z. (eds) Orbital Tumors. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1510-1_34

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1510-1_34

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1509-5

  • Online ISBN: 978-1-4939-1510-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation